CN1172717C - 一种治疗艾滋病的药物及其制备方法 - Google Patents
一种治疗艾滋病的药物及其制备方法 Download PDFInfo
- Publication number
- CN1172717C CN1172717C CNB001234838A CN00123483A CN1172717C CN 1172717 C CN1172717 C CN 1172717C CN B001234838 A CNB001234838 A CN B001234838A CN 00123483 A CN00123483 A CN 00123483A CN 1172717 C CN1172717 C CN 1172717C
- Authority
- CN
- China
- Prior art keywords
- epitope
- eldkwa
- medicine
- monoclonal antibody
- aids
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 208000030507 AIDS Diseases 0.000 title claims abstract description 48
- 238000000034 method Methods 0.000 title claims description 11
- 239000003814 drug Substances 0.000 claims abstract description 33
- 229920001184 polypeptide Polymers 0.000 claims abstract description 17
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 17
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 17
- 101800001690 Transmembrane protein gp41 Proteins 0.000 claims abstract description 14
- 230000036039 immunity Effects 0.000 claims abstract description 14
- 238000002360 preparation method Methods 0.000 claims abstract description 12
- 239000002671 adjuvant Substances 0.000 claims abstract description 11
- 210000004408 hybridoma Anatomy 0.000 claims abstract description 10
- 241000700605 Viruses Species 0.000 claims abstract description 9
- 239000000427 antigen Substances 0.000 claims abstract description 7
- 102000036639 antigens Human genes 0.000 claims abstract description 7
- 108091007433 antigens Proteins 0.000 claims abstract description 7
- 102000014914 Carrier Proteins Human genes 0.000 claims abstract description 4
- 108010078791 Carrier Proteins Proteins 0.000 claims abstract description 4
- 241001465754 Metazoa Species 0.000 claims abstract description 3
- 208000011580 syndromic disease Diseases 0.000 claims description 21
- 230000008878 coupling Effects 0.000 claims description 12
- 238000010168 coupling process Methods 0.000 claims description 12
- 238000005859 coupling reaction Methods 0.000 claims description 12
- 206010061598 Immunodeficiency Diseases 0.000 claims description 4
- 208000029462 Immunodeficiency disease Diseases 0.000 claims description 4
- 230000007910 cell fusion Effects 0.000 claims description 4
- 230000007813 immunodeficiency Effects 0.000 claims description 4
- 238000011091 antibody purification Methods 0.000 claims description 2
- 230000007812 deficiency Effects 0.000 abstract description 3
- 238000006386 neutralization reaction Methods 0.000 abstract 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 28
- 230000003472 neutralizing effect Effects 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 229940124321 AIDS medicine Drugs 0.000 description 2
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 201000000050 myeloid neoplasm Diseases 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- LLXVXPPXELIDGQ-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(2,5-dioxopyrrol-1-yl)benzoate Chemical compound C=1C=CC(N2C(C=CC2=O)=O)=CC=1C(=O)ON1C(=O)CCC1=O LLXVXPPXELIDGQ-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 206010035148 Plague Diseases 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- 230000000680 avirulence Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 238000001814 protein method Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1036—Retroviridae, e.g. leukemia viruses
- C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
- C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- AIDS & HIV (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Hematology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
本发明公开了一种治疗艾滋病的药及其制备方法,本发明治疗艾滋病的药,排除仅由4次重复的人免疫缺陷病毒跨膜蛋白gp41上的ELDKWA表位为抗原制备的单克隆抗体组成的药物,它包括至少一种单克隆抗体,所述制备单克隆抗体的抗原是2-4次重复的ELDKWA表位或者是2-4次重复的ELDKWA表位的变异表位,所述变异表位为ELEKWA、ELNKWA或ELDEWA。本发明药的制备方法为(1)、人工合成至少一条分别含有2-4次重复的人免疫缺陷病毒跨膜蛋白gp41上的ELDKWA表位或者含有2-4次重复的ELDKWA表位的变异表位的表位多肽,所述变异表位为ELEKWA、ELNKWA或ELDEWA;但排除仅为含有4次重复的ELDKWA表位的一条表位多肽的情况;(2)、将上述多肽分别耦联到载体蛋白或载体多肽上;(3)、用上述耦联物免疫动物;(4)、制备杂交瘤;(5)、将得到的抗体配以药用佐剂,制成药物。
Description
本发明涉及用生物工程技术制备的治疗艾滋病的药物及其制备方法,特别是涉及用艾滋病病毒膜蛋白的单克隆抗体制备的治疗艾滋病的药物及其制备方法。
艾滋病又称获得性免疫缺陷综合征,是由人类免疫缺陷病毒(HIV)引起的一种免疫性疾病。由于其传播迅速、病死率极高,且目前尚无特效治疗方法,更无疫苗可以预防,因而有“20世纪瘟疫”之称。
现有的用于临床的抗艾滋病药物仅能推迟发病期和延长病人的生命,并且价格昂贵,毒性大。最近国外抗艾滋病药物临床研究结果证明,针对HIV-1膜蛋白gp160(膜蛋白gp120及跨膜蛋白gp41的前体蛋白)上的几个特定中和表位的中和抗体(其中包括ELDKWA-表位特异性的单克隆抗体2F5)在被动免疫治疗中的组合使用能抑制HIV-1病毒的粘膜传染以及母婴传播,并能清除血液中的HIV-1病毒(Nature Medicine 1999,5:204;Nature Medicine 2000,6:200;Nature Medicine1999,5:211);人免疫缺陷病毒(HIV-1)跨膜蛋白gp41上的主要中和表位ELDKWA的表位特异性单克隆抗体能够体外抑制多种HIV-1病毒株感染靶细胞(J.Virology 1993,67:6642;AIDS Res.Human Retroviruses 1994,10:1651;AIDS1996,10:587)。
本发明的目的是提供一种有效的治疗艾滋病的药物,该药物可对付艾滋病病毒的变异。
本发明的另一个目的是提供一种制备上述治疗艾滋病的药物的方法。
为实现上述目的,本发明采取以下设计方案:一种治疗艾滋病的药,排除仅由4次重复的人免疫缺陷病毒跨膜蛋白gp41上的ELDKWA表位为抗原制备的单克隆抗体组成的药物,它包括至少一种单克隆抗体,所述制备单克隆抗体的抗原是2-4次重复的ELDKWA表位或者是2-4次重复的ELDKWA表位的变异表位,所述变异表位为ELEKWA、ELNKWA或ELDEWA。
本发明治疗艾滋病的药物优选由以下组分组成:
4次重复的ELDKWA-表位特异性的单克隆抗体
4次重复的ELEKWA-表位特异性的单克隆抗体
4次重复的ELNKWA-表位特异性的单克隆抗体
4次重复的ELDEWA-表位特异性的单克隆抗体。
一种制备权利要求1-2所述的治疗艾滋病的药物的方法,基本上包括以下步骤:
(1)、人工合成至少一条分别含有2-4次重复的人免疫缺陷病毒跨膜蛋白gp41上的ELDKWA表位或者含有2-4次重复的ELDKWA表位的变异表位的表位多肽,所述变异表位为ELEKWA、ELNKWA或ELDEWA;但排除仅为含有4次重复的ELDKWA表位的一条表位多肽的情况;
(2)、将上述表位多肽分别耦联到载体蛋白或载体多肽上形成耦联物;
(3)、用上述耦联物分别配以可接受的佐剂免疫动物;
(4)、采用常规的细胞融合技术分别制备杂交瘤;
(5)、将自上述不同杂交瘤细胞系得到的抗体纯化,混合制成治疗艾滋病的药物。
研究表明,针对HIV-1膜蛋白上中和表位的抗体在艾滋病治疗中能降低病毒的载量,延缓疾病的进行。本发明治疗艾滋病的药物是含有2-4次重复的抗人免疫缺陷病毒跨膜蛋白gp41上的主要中和表位ELDKWA表位及其变异表位(如ELEKWA、ELNKWA、ELDEWA)的多种抗体的药物,即使在艾滋病病毒产生变异的情况下,注射了该药物的人体内也会有相应的抗体来杀灭变异的病毒。
本发明的药物不但无毒性,而且在提高艾滋病的免疫治疗效果的同时,还可降低艾滋病治疗成本。
本发明采用人工合成表位多肽的方法来诱导、制备预先确定的表位特异性的单克隆抗体,克服了需要利用天然蛋白或重组蛋白免疫,然后大量筛选和鉴定才能得到预先确定的表位特异性的单克隆抗体的诸多复杂工作。
根据本发明,可以按照艾滋病病毒的变异情况,很快生产出其相应类型的药物,不需进行长时间的试验,降低生产成本。该技术将对世界预防医学研究产生重大影响,并将带来巨大的经济效益和社会效益。
下面结合非限制性具体实施例对本发明作进一步说明。
实施例一:由抗HIV-1 gp41上的中和表位ELDKWA的变异表位ELNKWA-表位特异性抗体为主要活性成分制成的治疗艾滋病的药物,由以下步骤生产:
(1)、人工合成一条含有人免疫缺陷病毒跨膜蛋白gp41上的4次重复的ELNKWA中和表位的表位多肽
CELNKWAGELNKWAGELNKWAGELNKWA;
(2)、利用MBS(m-maleimidobenzoyl-N-hydroxy succinimide ester)将上述表位多肽与载体蛋白BSA耦联;
(3)、将上述耦联物与福氏佐剂混合(两种物质的体积比为,耦联物∶福氏佐剂=1∶1)免疫Balb/c小鼠。第一次用完全福氏佐剂,以后每两周免疫一次,用不完全福氏佐剂。每次免疫的抗原剂量为:含10微克表位多肽的耦联物/次/只,共免疫3次;
(4)、将免疫后的小鼠脾细胞与小鼠骨髓瘤细胞系采用常规的细胞融合技术融合,并制备杂交瘤;
(5)、从上述杂交瘤细胞系中筛选出能产生预先定义的表位特异性的单克隆抗体的克隆,将提纯的抗体制成治疗艾滋病的药物。
该药物在实际应用中的使用剂量根据患者的病情来确定。
实施例二:由抗HIV-1 gp41上的中和表位ELDKWA及其变异表位ELNKWA、ELEKWA和ELDEWA的抗体为主要活性成分制成的治疗艾滋病的药物,由以下步骤生产:
(1)、人工合成4条分别含有人免疫缺陷病毒跨膜蛋白gp41上的中和表位ELDKWA及其变异表位ELNKWA、ELEKWA或ELDEWA的多肽:
C ELDKWA G ELDKWA G ELDKWA G ELDKWA
C ELNKWA G ELNKWA G ELNKWA G ELNKWA
C ELEKWA G ELEKWA G ELEKWA G ELEKWA
C ELDEWA G ELDEWA G ELDEWA G ELDEWA
(2)、利用戊二醛或MBS将上述多肽分别耦联到载体蛋白牛血清白蛋白上形成耦联物;
(3)、将上述耦联物分别与福氏佐剂混合(两种物质的体积比为,耦联物∶福氏佐剂=1∶1)后,分别免疫Balb/c小鼠。第一次用完全福氏佐剂,以后每两周免疫一次,用不完全福氏佐剂。每次免疫的抗原剂量为:含10微克表位多肽的耦联物/次/只,共免疫3次;
(4)、将免疫后的小鼠脾细胞与小鼠骨髓瘤细胞系采用常规的细胞融合技术融合,并制备杂交瘤;
(5)、从上述杂交瘤细胞系筛选出能产生预先定义的4种表位特异性的单克隆抗体的克隆。
(6)、自上述杂交瘤细胞系分别得到抗HIV-1 gp41上的中和表位ELDKWA及其变异表位ELNKWA、ELEKWA、ELDEWA的4种单克隆抗体,将上述抗体混合,制成治疗艾滋病的药物,其中,各种抗体的加入量由适用人群的统计学处理得出的各种表位的出现概率进行调整。
使用本发明的药物,可以明显抵抗艾滋病病毒的变异,降低艾滋病病毒的载量,延缓疾病的进行,最后达到治愈的目的。
Claims (3)
1、一种治疗艾滋病的药,排除仅由4次重复的人免疫缺陷病毒跨膜蛋白gp41上的ELDKWA表位为抗原制备的单克隆抗体组成的药物,它包括至少一种单克隆抗体,所述制备单克隆抗体的抗原是2-4次重复的ELDKWA表位或者是2-4次重复的ELDKWA表位的变异表位,所述变异表位为ELEKWA、ELNKWA或ELDEWA。
2、根据权利要求1所述的一种治疗艾滋病的药,其特征在于:它由以下组分组成:4次重复的ELDKWA-表位特异性的单克隆抗体
4次重复的ELEKWA-表位特异性的单克隆抗体
4次重复的ELNKWA-表位特异性的单克隆抗体
4次重复的ELDEWA-表位特异性的单克隆抗体。
3、一种制备权利要求1-2所述的治疗艾滋病的药物的方法,基本上包括以下步骤:
(1)、人工合成至少一条分别含有2-4次重复的人免疫缺陷病毒跨膜蛋白gp41上的ELDKWA表位或者含有2-4次重复的ELDKWA表位的变异表位的表位多肽,所述变异表位为ELEKWA、ELNKWA或ELDEWA;但排除仅为含有4次重复的ELDKWA表位的一条表位多肽的情况;
(2)、将上述表位多肽分别耦联到载体蛋白或载体多肽上形成耦联物;
(3)、用上述耦联物分别配以可接受的佐剂免疫动物;
(4)、采用常规的细胞融合技术分别制备杂交瘤;
(5)、将自上述不同杂交瘤细胞系得到的抗体纯化,混合制成治疗艾滋病的药物。
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB001234838A CN1172717C (zh) | 2000-08-18 | 2000-08-18 | 一种治疗艾滋病的药物及其制备方法 |
PCT/CN2001/001192 WO2002032452A1 (fr) | 2000-08-18 | 2001-07-20 | Medicament pour le traitement du sida et son procede de preparation |
AU2002214920A AU2002214920A1 (en) | 2000-08-18 | 2001-07-20 | Composition for aids and method producing it |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB001234838A CN1172717C (zh) | 2000-08-18 | 2000-08-18 | 一种治疗艾滋病的药物及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1339318A CN1339318A (zh) | 2002-03-13 |
CN1172717C true CN1172717C (zh) | 2004-10-27 |
Family
ID=4589903
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB001234838A Expired - Fee Related CN1172717C (zh) | 2000-08-18 | 2000-08-18 | 一种治疗艾滋病的药物及其制备方法 |
Country Status (3)
Country | Link |
---|---|
CN (1) | CN1172717C (zh) |
AU (1) | AU2002214920A1 (zh) |
WO (1) | WO2002032452A1 (zh) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004029201A2 (en) * | 2002-09-24 | 2004-04-08 | Frontier Biotechnologies Co., Ltd | Peptide derivative fusion inhibitors of hiv infection |
EP3383902A1 (en) | 2015-12-05 | 2018-10-10 | Centre Hospitalier Universitaire Vaudois | Hiv binding agents |
WO2020012435A1 (en) | 2018-07-13 | 2020-01-16 | Lausanne University Hospital | Hiv binding agents |
US20220267416A1 (en) | 2019-07-15 | 2022-08-25 | Lausanne University Hospital | Hiv binding agents |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5459060A (en) * | 1989-08-24 | 1995-10-17 | Bioclonetics Incorporated | Human monoclonal antibodies directed against the transmembrane glycoprotein (gp41) of human immunodeficiency virus-1 (HIV-1) |
JPH08503704A (ja) * | 1992-11-23 | 1996-04-23 | プレジデント アンド フェロウズ オブ ハーバード カレッジ | Gp41変異体とhiv治療剤としてのそれらの使用 |
EP0702693A1 (en) * | 1993-06-09 | 1996-03-27 | Connaught Laboratories Limited | Tandem synthetic hiv-1 peptides |
US5380668A (en) * | 1993-07-06 | 1995-01-10 | University Of Utah Research Foundation | Compounds having the antigenicity of hCG |
EP0725825B1 (en) * | 1993-09-11 | 2001-02-21 | Polymun Scientific Immunbiologische Forschung GmbH | Peptides that elicit neutralizing antibodies against genetically divergent hiv-1 strains |
-
2000
- 2000-08-18 CN CNB001234838A patent/CN1172717C/zh not_active Expired - Fee Related
-
2001
- 2001-07-20 AU AU2002214920A patent/AU2002214920A1/en not_active Abandoned
- 2001-07-20 WO PCT/CN2001/001192 patent/WO2002032452A1/zh active Application Filing
Also Published As
Publication number | Publication date |
---|---|
CN1339318A (zh) | 2002-03-13 |
WO2002032452A1 (fr) | 2002-04-25 |
AU2002214920A1 (en) | 2002-04-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6830462B2 (ja) | 抗体および抗体含有組成物 | |
AT398080B (de) | Immortalisierte zellinie, verfahren zu ihrer herstellung und verfahren zur herstellung von monoklonalen antikörpern sowie diagnoseverfahren und -mittel | |
US20030003440A1 (en) | Novel CCR5 epitope and antibodies against it | |
JPH06502539A (ja) | Hiv−1 gp120のv3ループおよびcd−4結合部位に特異的な中和ヒトモノクローナル抗体 | |
EP0822941A1 (en) | Monoclonal antibodies against hiv-1 and vaccines made thereof | |
RU2535034C2 (ru) | Лекарственное средство и способ профилактики инфицирования вич, профилактики и лечения заболеваний, вызываемых вич или ассоциированных с вич, в том числе спида | |
US6132721A (en) | Non-Toxic immunogens derived from a retroviral regulatory protein, antibodies, preparation method therefor, and pharmaceutical compositions containing same | |
JPH09509164A (ja) | 免疫グロブリンaを用いた炎症を予防及び治療するための組成物並びに方法 | |
WO2012018284A1 (ru) | Лекарственное средство и способ профилактики инфицирования вич, профилактики и лечения заболеваний, вызываемых вич или ассоциированных с вич, в том числе спида | |
KR930702509A (ko) | 사람 면역결핍 바이러스(hiv)면역치료제 | |
CN1172717C (zh) | 一种治疗艾滋病的药物及其制备方法 | |
US6200575B1 (en) | Non-toxic immunogens derived from a retroviral regulatory protein antibodies preparation process and pharmaceutical compositions comprising them | |
US6124132A (en) | Use of anti-HIV IGA antibodies for producing immunological protection against the human immunodeficiency virus | |
US20020086022A1 (en) | Neutralizing antibody and immunomodulatory enhancing compositions | |
CN1339319A (zh) | 一种治疗艾滋病的药物及其制备方法 | |
WO1991010742A1 (en) | Monoclonal antibody specific for non-immunodominant epitope of hiv proteins | |
CN1339320A (zh) | 一种艾滋病疫苗及其制备方法与应用 | |
RU2217166C2 (ru) | Гуманизированные антитела, которые распознают веротоксин ii, и продуцирующая их линия клеток | |
CA2481325C (en) | Anti-hiv composition, production method thereof and medicament | |
CN1238499C (zh) | 艾滋病病毒0型株的一种抗体及其生产细胞系与应用 | |
AP255A (en) | A method of inoculation with an antigenic peptide. | |
JPH05506565A (ja) | 抗炭水化物抗体および炭水化物抗原を使用する後天性免疫不全症候群(aids)およびaids関連症候群(arc)の処置のための薬剤および方法 | |
EP1366080B1 (en) | Natural antibodies active against hiv virus | |
WO1998001476A1 (en) | Highly synergistic neutralization of hiv through combinations of monoclonal and polyclonal antibodies | |
JP3725899B2 (ja) | Hivに対して使用するための多分岐ペプチド構築物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C06 | Publication | ||
PB01 | Publication | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C19 | Lapse of patent right due to non-payment of the annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |